首页> 外文期刊>Journal of Clinical Pathology >A parallel comparison of T-cell clonality assessment between an in-house PCR assay and the BIOMED-2 assay leading to an efficient and cost-effective strategy
【24h】

A parallel comparison of T-cell clonality assessment between an in-house PCR assay and the BIOMED-2 assay leading to an efficient and cost-effective strategy

机译:内部PCR测定法和BIOMED-2测定法之间T细胞克隆性评估的平行比较,导致了一种有效且具有成本效益的策略

获取原文
获取原文并翻译 | 示例
       

摘要

Aims Diagnosis of T-cell lymphoproliferation is sometimes challenging, and in certain instances pathologists rely heavily on the clonality assessment results of T-cell receptor (TCR) gene rearrangement (TCR-GR). Many investigators have designed various in-house primer sets for PCR-based study targeting different loci of TCR genes. In recent years, the commercial BIOMED-2 protocols have become available. The in-house primers are very cheap while the BIOMED-2 primers are expensive. This parallel study aimed to compare the sensitivity of the in-house TCRG primers (two reactions) and the BIOMED-2 TCR primers (six reactions) in an attempt to develop a sensitive and cost-effective strategy for TCR-GR assessment. Methods PCR-based analysis was performed on 69 samples of T-lineage neoplasms including 60 formalin-fixed paraffin-embedded (FFPE) tissues, 5 samples from peripheral blood (PB) and 4 samples from bone marrow (BM) aspirate. Results Forty-seven (78%) FFPE and all PB or BM aspirate samples yielded control DNA products suitable for clonality assessment including 4 precursor and 50 mature T-cell neoplasms. The detection rates of clonal TCR-GR were 63% (34/54) by the two in-house TCRG primers, 85% (46/54) by all six BIOMED-2 reactions, 91% (49/54) by combining the in-house and BIOMED-2 TCRG reactions and 94% (51/54) by combining the in-house and all BIOMED-2 reactions. By using the in-house and BIOMED-2 TCRG reactions with a total of four tubes, clonal TCR-GR was detected in 91% of the cases. The reagent cost for this combination was one-third of that for the six BIOMED-2 reactions and the detection rate was also higher than the latter alone (91% vs 85%). Conclusions As the in-house primers were custom made and are much cheaper than the commercial kits, the authors concluded that this four-tube strategy was cost-effective and efficient for TCR-GR clonality assessment.
机译:目的T细胞淋巴增殖的诊断有时具有挑战性,在某些情况下,病理学家严重依赖T细胞受体(TCR)基因重排(TCR-GR)的克隆性评估结果。许多研究人员设计了各种内部引物组,用于针对TCR基因不同基因座的基于PCR的研究。近年来,商业化的BIOMED-2协议已经可用。内部引物非常便宜,而BIOMED-2引物很昂贵。这项平行研究旨在比较内部TCRG引物(两个反应)和BIOMED-2 TCR引物(六个反应)的敏感性,以期开发出灵敏且经济高效的TCR-GR评估策略。方法对69份T系肿瘤标本进行PCR分析,包括60份福尔马林固定石蜡包埋(FFPE)组织,5份外周血(PB)和4份骨髓(BM)抽吸物。结果四十七(78%)个FFPE和所有PB或BM抽吸样品产生了适合克隆性评估的对照DNA产物,包括4个前体和50个成熟的T细胞肿瘤。两种内部TCRG引物对克隆TCR-GR的检出率为63%(34/54),对所有6种BIOMED-2反应的检出率为85%(46/54),通过结合使用两种方法的检出率为91%(49/54)。内部和BIOMED-2的TCRG反应和94%(51/54)的反应通过结合内部和所有BIOMED-2的反应进行。通过将内部和BIOMED-2 TCRG反应与总共四个试管一起使用,在91%的病例中检测到了克隆性TCR-GR。此组合的试剂成本是六个BIOMED-2反应的试剂成本的三分之一,检出率也高于后者(91%对85%)。结论由于内部引物是定制的,并且比市售试剂盒便宜得多,因此作者得出结论,这种四管策略对于TCR-GR克隆性评估是经济高效的。

著录项

  • 来源
    《Journal of Clinical Pathology》 |2011年第6期|p.536-542|共7页
  • 作者单位

    Department of Pathology,Chi-Mei Medical Center, Tainan Taiwan;

    Department of Histopathology,Addenbrooke's Hospital,University of Cambridge,Cambridge, UK;

    Department of Pathology,Chi-Mei Medical Center, Tainan Taiwan;

    Department of Pathology,Chi-Mei Medical Center, Tainan Taiwan;

    Department of Pathology,Chi-Mei Medical Center, Tainan Taiwan;

    Department of Histopathology,Addenbrooke's Hospital,University of Cambridge,Cambridge, UK;

    Department of Histopathology,Addenbrooke's Hospital,University of Cambridge,Cambridge, UK;

    Department of Pathology,Chi-Mei Medical Center, Tainan Taiwan,department of Pathology,Taipei Medical University, Taipei, Taiwan;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 01:35:43

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号